Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ateganosine - MAIA Biotechnology

Next Previous
Drug Profile

Ateganosine - MAIA Biotechnology

Alternative Names: 2'-Deoxythioguanosine; 6-thio-2’-deoxyguanosine - MAIA Biotechnology; 6-thio-dG - MAIA Biotechnology; THIO - MAIA Biotechnology

Latest Information Update: 13 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MAIA Biotechnology
  • Class Amines; Antineoplastics; Deoxyribonucleosides; Purines; Small molecules; Thiones
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Small cell lung cancer; Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Preclinical Glioma; Liver cancer; Small cell lung cancer

Most Recent Events

  • 06 Jun 2025 Updated efficacy data from the phase II THIO-101 trial in Non-small cell lung cancer released by MAIA Biotechnology
  • 05 Jun 2025 Updated efficacy data from the phase II THIO-101 trial in Non-small cell lung cancer released by MAIA Biotechnology
  • 08 Apr 2025 Maia Biotechnology plans a phase III trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) (IV, Infusion) in July 2025 (NCT06908304)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top